v3.25.2
BUSINESS ACQUISITIONS (Tables)
6 Months Ended
Jun. 30, 2024
Business Combination [Abstract]  
Business Combination, Pro Forma Information The following unaudited pro forma combined financial information reflects the consolidated statement of operations of the Company as if the acquisition of LifeLabs had occurred as of January 1, 2023. The pro forma information includes adjustments primarily related to the amortization of acquired intangible assets, interest expense associated with debt of LifeLabs which was extinguished prior to the acquisition, interest expense associated with senior notes issued to fund the acquisition, the impact on depreciation expense of recording acquired property, plant and equipment at fair value, and transaction costs related to the LifeLabs acquisition. The pro forma combined financial information does not include the estimated annual synergies expected to be realized upon completion of the integration of LifeLabs and therefore is not indicative of the results of operations as they would have been had the transaction been effected on the assumed date (in millions, except per share data).
Three Months Ended June 30, 2024Six Months Ended June 30, 2024
Pro forma net revenues$2,577 $5,112 
Pro forma net income attributable to Quest Diagnostics$234 $425 
Pro forma earnings per share attributable to Quest Diagnostics' common stockholders:
Basic$2.09 $3.80 
Diluted$2.07 $3.77